NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4 Portfolio News / By Karina Tin October 19, 2020 NGM Expands Oncology Portfolio with First Immuno-Oncology Development Candidate, NGM707, a Novel Dual Antagonist Antibody Inhibiting ILT2 and ILT4 Read More »
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program Portfolio News / By Karina Tin October 19, 2020 ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program Read More »
eFFECTOR Appoints Premal Patel, M.D., Ph.D., as Chief Medical Officer Portfolio News / By Karina Tin October 15, 2020 eFFECTOR Appoints Premal Patel, M.D., Ph.D., as Chief Medical Officer Read More »
Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin October 14, 2020 Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update Read More »
A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics Portfolio News / By Karina Tin October 6, 2020 A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics Read More »
Arcus Biosciences: Jennifer Jarrett Returns as Chief Operating Officer Portfolio News / By Karina Tin October 1, 2020 Arcus Biosciences: Jennifer Jarrett Returns as Chief Operating Officer Read More »
Carmot Therapeutics Expands Leadership Team and Closes $47M Series C Financing to Advance Novel Incretin Receptor Modulators Through Phase 2 Studies Portfolio News / By Karina Tin September 30, 2020 Carmot Therapeutics Expands Leadership Team and Closes $47M Series C Financing to Advance Novel Incretin Receptor Modulators Through Phase 2 Studies Read More »
Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases Portfolio News / By Karina Tin September 17, 2020 Synthekine Launches with $82 Million Series A Financing to Advance Pipeline of Engineered Cytokine Therapeutics Optimized for Cancer and Autoimmune Diseases Read More »
Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors Portfolio News / By Karina Tin September 16, 2020 Revolution Medicines Reports Preclinical Tumor Regressions Induced by First-in-Class KRAS-G12D(ON) Inhibitors Read More »
Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies Portfolio News / By Karina Tin September 15, 2020 Hexagon Bio Closes $47 Million in Series A Financing to Advance Novel Oncology and Infectious Disease Therapies Read More »
